NICE adds final new option on Roche's MabThera for advanced follicular lymphoma
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has said today in final and binding guidance that Roche's MabThera (rituximab) can be used alongside chlorambucil to treat patients with advanced follicular lymphoma. The dual therapy comes on top of four new MabThera regimens detailed in previous draft guidance.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.